The confusion intensifies when someone has been stuck for two months, then starts regaining weight despite consistent dosing and no obvious dietary changes
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a Phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
This was a landmark moment because it represented global recognition of GLP-1 medications as a legitimate long-term treatment for obesity rather than a temporary or supplementary intervention
I expected patients using these medications adjunctively with insulin to have potentially more hospitalizations and clinical visits from adverse GI events
147 SiegertE.PaulF.RotheM.WeylandtK
Exosomes used in aesthetic treatments are thoroughly purified, tested, and free of DNA, allowing them to interact safely with your cells